Tobacco Induced Diseases (Oct 2019)

The effect of highly absorbed curcumin on an oxidized LDL in patients with COPD

  • Masafumi Funamoto,
  • Ayumi Katayama,
  • Yoichi Sunagawa,
  • Yasufumi Katanasaka,
  • Yusuke Miyazaki,
  • Hajime Yamakage,
  • Noriko Satoh-Asahara,
  • Maki Komiyama,
  • Hiromichi Wada,
  • Koji Hasegawa,
  • Tatsuya Morimoto

DOI
https://doi.org/10.18332/tid/112085
Journal volume & issue
Vol. 17, no. 1

Abstract

Read online

Objective COPD is primarily caused by regular smoking and is associated with a high frequency of coronary artery disease. There is growing recognition that the inflammation in COPD is not only confined to the lungs but also involves the systemic circulation and can impact nonpulmonary organs, including blood vessels. α1-antitrypsin-low-density lipoprotein (AT-LDL) complex is an oxidized LDL that accelerates atherosclerosis. Curcumin, one of the best-investigated natural products, is a powerful antioxidant. However, the effects of curcumin on AT-LDL remain unknown. We hypothesized that Theracurmin®, a highly absorptive curcumin with improved bioavailability using a drug delivery system, ameliorates the inflammatory status in subjects with COPD. Methods This is a randomized, double-blind, parallel-group study. The subjects were men or women (age, 20–85 years) who met the following criteria: 1) patients with COPD at stage 0, I, or II according to the definition by the Japanese Respiratory Society and 2) patients who have never smoked at least for the past 4 months. Subjects were randomly assigned to receive 90 mg Theracurmin® or placebo twice a day for 24 weeks, and changes in inflammatory parameters were evaluated. Results There were no differences between the Theracurmin® and placebo groups in terms of age, male/female ratio, or body mass index in 39 evaluable subjects. The percent changes in blood pressure and hemoglobin A1c and LDL-cholesterol, triglyceride, or high-density lipoprotein-cholesterol levels after treatment were similar for the two groups. However, the percent change in the AT-LDL level was significantly (P=0.020) lower in the Theracurmin® group compared with the placebo group. However, LDL-C, IL-6 and TNF-α were not changed. Conclusions Theracurmin® reduced levels of atherosclerotic AT-LDL, which may lead to the prevention of future cardiovascular events in patients with COPD.

Keywords